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Min Hee Kang and Hee Myung Park*Abstract
Background: Recent studies have assessed the therapeutic potential and drawbacks of mesenchymal stem cells
(MSCs). The adverse reactions of intravenous transplantation of bone marrow (BM)-derived MSCs were examined at
varying doses and frequencies of administration.
Nine healthy beagle dogs were purchased from a commercial laboratory. The dogs were distributed equally (n = 3
per group) and randomly into three groups. All dogs received allogeneic BM-derived MSCs: 2 × 106 once (group A),
2 × 107 once (group B), and 2 × 106 for three consecutive days (group C). Various laboratory examinations, multi-
detector computed tomography features and histopathology were evaluated to clarify the clinical and diagnostic
features of adverse reactions of MSCs administration, prior to receiving MSCs (pre procedure) and on days 1, 3, and
7 post transplantation.
Results: Only one dog had clinical signs during and after MSCs transplantation. Dogs receiving 2 × 106 MSCs
showed increased numbers of lymphocytes but the total white blood cell counts were not elevated (P < 0.01).
Multi-detector computed tomography (MDCT) revealed pulmonary parenchymal changes in one dog and
histopathologic examination revealed pulmonary parenchymal edema and hemorrhage in four dogs. The presence
of pulmonary thromboembolism was not detected in either examination.
Conclusions: We considered the presence of pulmonary edema and hemorrhage as possible adverse reactions
after intravenous MSCs transplantation; however these results should be cautiously interpreted.
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Cell-based therapies hold great potential for the treat-
ment of a number of life-threatening diseases. Accord-
ingly, in recent years, extensive research efforts were
concentrated on enhancing the effectiveness of cell-
based therapies [1]. Recent studies have also focused on,
the clinical efficacy of bone marrow mononuclear cell
transplantation. Results of these studies have been posi-
tive, and offer valuable therapeutic options for the treat-
ment of myocardial infarction [2,3], lung injury [4], limb
ischemia [5], and stroke [1,6]. Multipotent stem cells
have the ability to self-renew and differentiate into a lim-
ited number of cell types. It has been demonstrated that* Correspondence: parkhee@konkuk.ac.kr
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reproduction in any medium, provided the orstem cells interact with supportive cells that function as
a scaffold and help restore the structure and function at
the target region in a number of body systems.
Peripheral delivery of stem cells has become one the
popular methods of transplantation owing to its nonin-
vasive nature. However, the effect and adverse reactions
arising from peripheral stem cell therapy have not been
fully characterized [7-9]. Incidence of adverse reactions,
including myocardial infarction and embolism following
stem cell transplantation, have been reported [8,9]. High
pulmonary entrapment of systemically administered
stem cells limits their homing and, hence, effectiveness
of cell therapy [10,11]. Additionally, it has been found that
the size and volume of stem cells and the method of trans-
plantation has an influence on the results of the therapy.
Based on these findings, we hypothesized that intraven-
ously injected bone marrow (BM)-derived mesenchymalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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dosages.
The purpose of this study was to identify the adverse re-
actions arising from intravenous transplantation of bone
marrow BM-derived MSCs at different doses and injection
frequency. We used various laboratory examinations,
multi-detector computed tomography features and histo-
pathology to establish the clinical and diagnostic features
of adverse reactions arising from MSCs transplantation.
Methods
Animals
Nine healthy, middle-aged, intact, female beagle dogs
(weight, 9.2 ± 2.69 kg; range 5.4-12.5 kg) without clinical
signs of any disease were used. Prior to the study, all dogs
were subjected to thorough physical examination. Blood
cell counts and plasma biochemical analyses were per-
formed. Resting electrocardiography (ECG); 2D, M-Mode
and Doppler echocardiography; and antigen kit-based
heart worm infection screening test (Anigen Heartworm
Ag 2.0, Animal Genetics, Seoul, Republic of Korea) to rule
out pre-existing cardiac, pulmonary or systemic diseases,
were performed. All dogs were fed and housed in an iden-
tical manner during the 7-day adaptation leading to the
experiment. The study protocol was approved by the Insti-
tutional Animal Care and Use Committee of Konkuk
University.
Isolation and characterization stem cells
Allogeneic canine MSCs were isolated according to estab-
lished methods [12]. Briefly, 10 milliliters of canine BM
was aspirated from the greater tubercle of the humerus in
a 20 ml syringe precoated with 100 U/ml heparin.
Anesthesia was induced by intramuscular injection of a
combination of medetomidine hydrochloride (0.03 mg/kg,
Domitor, Pfizer Animal Health, Exton, PA) and tileta-
mine/zolazepam (1.5 mg/kg, Zoletil, Virbac, Carros,
France). After washing three times with phosphate buff-
ered saline (PBS; pH 7.4), BM mononuclear cells were
isolated by Ficoll (GE healthcare Lifescience, Dong-il Sci-
entific Co., Seoul, Republic of Korea) (15 ml) density cen-
trifugation (4°C, 1,100 g for 30 minutes). Mononuclear
cells (5 × 106 cells) were placed in a 100 mm2 culture dish
and cultivated in low-glucose Dulbecco Modified Eagle’s
Medium (Welgene Inc., Seoul, Republic of Korea) contain-
ing 10% fetal bovine serum and 1% penicillin/strepto-
mycin/amphotericin B in a humidified incubator, at 37°C
in the presence of 5% CO2. After 7 days, non-adherent
cells were removed during the replacement of the spent
medium. After 10–14 days of culture, the cells were har-
vested and subcultured. MSCs were culture expanded; cells
in passage 3 without freezing were used for our studies.
Prior to transplantation, MSCs were analyzed for the
cell surface markers (CD 9, CD 34, CD 44, and CD 45)by using fluorescence activated cell sorter (FACScan,
Becton-Dickinson, Mountain View, CA) as reported previ-
ously [12]. A total of 106 cells were stained with each
monoclonal antibody. Hematopoietic stem cell markers,
such as, mouse anti-canine CD 34 (MCA2411F, AbD
Serotec, Oxford, UK) and mouse anti-canine CD 45
(MCA1042F, AbD Serotec, Oxford, UK) were used as nega-
tive MSC markers. Mouse anti-human CD 9 (MCA469F,
AbD Serotec, Oxford, UK) and rat anti-canine CD 44
(MCA1041A488, AbD Serotec, Oxford, UK) were used as
MSC positive markers. Non-staining MSCs were used as
controls. Using a FACScan apparatus, at least 10,000 MSCs
were analyzed for the presence of cell surface markers in
each experiment. Majority of the cells were strongly posi-
tive for CD9 and CD44, whereas hematopoietic stem cell
markers were relatively undetectable (Figure 1).
Post MSCs transplantation animal care and monitoring
All dogs received allogeneic BM-derived MSCs trans-
plants: 2 × 106 once (group A, n = 3), 2 × 107 once (group
B, n = 3), and 2 × 106 on three consecutive days (group C,
n = 3). The MSC dose was selected on the basis of the
mean body mass and was equivalent to the effective dose
used in earlier studies involving humans and rat models
[1,6,7]. The cells were harvested and washed with PBS at
least three times, and resuspended in 20 ml of the saline
solution. Freshly harvested allogeneic MSCs (approximate
diameter, 20 μm) were infused into the animals through a
peripheral catheter over a period of 20–30 minutes.
Dogs were evaluated prior to allogeneic MSC transplant-
ation, as well as on days 1, 3, and 7 post-transplantation.
Occurrence of adverse events was routinely assessed. A
physical examination, complete blood count (CBC) with
differentials, arterial blood gas (i-STAT, Abbott Laborator-
ies, Abbott Park, IL) and serum chemistry panel were
performed. Coagulation profiles (Behnk Elektronik Coagu-
lator, Norderstedt, Germany) including a prothrombin
time (PT), activated partial thromboplastin time (aPTT),
fibrinogen degradation products (FDP) (Neodin Veterin-
ary Diagnosis Laboratories, Korea), and D-dimer (Nyco-
Card Reader II, AS Company, Oslo, Norway) were also
evaluated. Hemodynamic changes were monitored by
measuring indirect arterial blood pressure (Cardell Model
9401, Sharn Veterinary Inc., Tampa, FL), performing 6
leads ECG (Cardiofax GEM ECG-9020 K, Nihon Kohden,
Japan) and by complete echocardiographic examination
(Logiq400, GE healthcare, Milwaukee, WI), which in-
cluded transthoracic 2-D, M-mode, spectral, and color
flow Doppler. All echocardiographic measurements were
followed previously described methods [13-15].
Real-time RT-PCR
Immunological and inflammatory responses were evalu-
ated by analyzing cytokine [Tumor necrosis factor-alpha
Figure 1 Flow cytometry analysis of the MSCs from one dog. The cells were harvested from the 3rd passage and the expression of CD9 and
CD 44 were identified. CD 34 (4.69%) and CD45 (5.19%), hematopoietic stem cell markers, were used as negative MSCs marker. CD9 (99.63%) and
CD44 (99.39%) were used as MSCs positive markers. Non-staining MSCs were used as controls.
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Blood samples were obtained by jugular venipuncture
(1 ml) at 0, 1, 3, and 7 days after the allogeneic MSCs
transplantation. Total cellular ribonucleic acid (RNA)
was extracted from whole blood by using a commercial
kit (RNA blood mini kit, Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s protocols. The extracted
total RNA was stored at −70°C until further analysis. All
primers and probes used in this study were designed ac-
cording to the previous studies (TNF-α [16]; GAPDH,Table 1 Cytokine primers for RT-PCR
Primer set Primer sequence 5′ fluoroph
GAPDHa Forward TCAACGGATTTGGCCGTATTGG FAM
Reverse TGAAGGGGTCATTGATGGCG
TNF-αb Forward GAGCCGACGTGCCAATG FAM
Reverse CAACCCATCTGACGGCACTA
IL-4a Forward GCTCCAAAGAACACAAGCGA FAM
Reverse CATGCTGCTGAGGTTCCTGT
IL-6a Forward CTCTCCACAAGCGCCTTCTC FAM
Reverse TGAAGTGGCATCATCCTTGG
IL-10a Forward CGACCCAGACATCAAGAACC FAM
Reverse CACAGGGAAGAAATCGGTGA
aPrimer and probe were synthesized according to the previous report [17].
bPrimer and probe were synthesized according to the previous report [14].IL-4, IL-6 and IL-10 [17]). The sequences of the primers
and probes are shown in Table 1. Real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) was
performed using the one-step RT-PCR mixtures and
PCR-amplified in a sequence detection system (ABI
7500/7500 Fast Real-Time PCR System, Applied Biosys-
tems) and analyzed according to the diagnostic proce-
dures provided in the manufacturer’s manual. The
comparative threshold (CT) values were used to deter-
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GAPDH acts as a standard variate. The CT value of
GAPDH was subtracted from the CT value of the target
cytokines (ΔCT) to normalize for differences in the
amount of total nucleic acid added to each reaction and
the efficiency of the RT step. The data output was
expressed as a fold-difference of expression levels (quan-
titation value) [18].
Multi-detector computed tomography scanning
MDCT (Asteion 4®, Toshiba, Tokyo, Japan) of cardiovas-
cular and pulmonary system with contrast was performed
two times in all groups (before and 7 days after the BM
MSCs treatment) to evaluate the changes that occurred
after allogeneic MSC transplantation. Blood was pulled
prior to anesthesia, CT and contrast administration at
each time. Anesthesia was induced with i.v. propofol
(Anepol; Ha Na Pharm, Seoul, Republic of Korea) (4 mg/
kg) followed by endotracheal intubation with a cuffed
endotracheal tube and was maintained with 2.5% isoflur-
ane (Forane Soln; Choong Wae Pharm, Seoul, Republic of
Korea) in oxygen. Technical parameters included 1-mm
collimation, 1.0 pitch, 150 kV, 120 mA, and 0.75-sec scan
time. Respiration was suspended during scanning (30 sec).
Non-inonic contrast medium (Omnipaque; GE healthcare,
Seoul, Republic of Korea) (850 mgl/kg) was i.v. injected
with auto injector (CT9000; Liebel-Flarsheim, Cincinnati,
OH) (1 ml/sec) for aortic and venous phase scanning. A
volume-rendered three-dimensional reconstructed image
was obtained for more information. Images were recon-
structed at 1.6-mm intervals using a standard algorithm.
The presence of emboli as well as arterial and parenchy-
mal changes were systematically evaluated and recorded
for each lung lobe by three veterinarians who had experi-
ence in performing CT pulmonary angiography. They
were blinded to the dog and time of CT (pre vs post),
scores were performed separately on 4 studies/pre and
post contrast. PTE positivity in arteries of each lung lobe
was determined with the help of reviewer consensus. Posi-
tive or negative was assigned only the case of unanimous
decision.
Histopathology
To evaluate the pulmonary parenchymal lesions and
PTE, histopathologic examinations were performed. One
day after the last evaluation, all dogs were sedated by ad-
ministering a combination of medetomidine hydrochlor-
ide (0.03 mg/kg) and tiletamine/zolazepam (1.5 mg/kg).
Following this, animals were euthanized by intravenous
injection of sodium pentobartital (80–100 mg/kg). To
reduce the tissue artifact, the recommended dose was
administered, and necropsy was performed within an
hour of death. Previous experiments in the author’s lab
using this same technique in canine did not affectpulmonary histopathology (unpublished data). Two sam-
ples of each lung lobes were randomly collected and
evaluated blindly by two pathologists. Four micrometer-
thick sections were prepared, mounted on slides, and
stained with hematoxylin/eosin. The presence or absence
of emboli, vascular inflammation, and changes in the lung
parenchyma were recorded for each vessel and subseg-
mental zone. The final evaluations were derived based on
agreement between the two pathologists.
Statistical analysis
All data are expressed as mean ± SD. Each profile was an-
alyzed over time using repeated measured analysis of vari-
ance (ANOVA). In addition, the changes from base line in
those parameters were also compared between groups by
using repeated ANOVA experiments in conjunction with
scheffe test. The ‘Mann–Whitney U test’ was used to com-
pare the differences in diagnostic values between MDCT
imaging and histopathologic examination. Post hoc power
calculations were conducted in cases where significant re-
sults were not detected in each repeated ANOVA model
with an alpha of 0.05, the current study will have at least
80% power to detect differences in diagnostic values. Stat-
istical significance was defined as observed power (1-β) >
0.80 and P (α) < 0.05. SPSS version 19.0, G*Power version
3 (Germany) and EXCEL 2010 (Microsoft, Redmond)
were used to perform statistical analyses.
Results
Clinical assessment
Most animals had no noticeable clinical findings after
allogeneic MSC transplantation. One dog (no. 8 dog) in
group C experienced vomiting 5–10 minutes after the
first and second administration. A progressive cough
was also observed on day 7. Vital signs such as body
temperature, respiratory rate, heart rate, and systolic
blood pressure were recorded for all nine dogs. In no. 8
dog, body weight was slightly decreased from 8.6 kg at
day 0 to 8.4 kg at day 7. Respiration rate was increased
from 36 bpm at day 0 to 66 bpm at day 7. In the same
dog, increases were also noted in heart rate (120 bpm at
day 0 to 156 bpm at day 7) and body temperature (37.8°C
at day 0 to 39.5°C) at day 7. However, there were no sig-
nificant differences of vital sign values within and between
groups A, B, and C (observed power < 0.80, P > 0.05).
Animal monitoring
To examine the possibility of immunologic reaction, in-
flammation, systemic adverse response, and hypercoagu-
lability, we analyzed serial blood examination results,
coagulation profiles, ECG, echocardiography, and cyto-
kine expression patterns before and after allogeneic
MSCs transplantation. The post-transplantation serum
chemistry and arterial blood gas results were within
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platelet counts did not show significant changes. Al-
though the total WBC count remained unchanged, the
relative population of various cell types changed signifi-
cantly in group A and C. The changes of monocytes,
segmented neutrophils, and lymphocytes by time course
[monocyte: F(3,4) = 8.005, P = < 0.05, partial η2 = 0.572,
observed power = 0.969, segmented neutrophils: F(3,4) =
17.675, P = < 0.05, partial η2 = 0.757, observed power =
1.000, lymphocytes: F(3,4) = 16.274, P = < 0.05, partial
η2 = 0.731, observed power = 1.000] and the time by
group interaction [monocyte: F(6,10) = 4.445, P = < 0.05,
partial η2 = 0.597, observed power = 0.927, segmented
neutrophils: F(6,10) = 5.432, P = < 0.05, partial η2 = 0.644,
observed power = 0.969, lymphocytes: F(6,10) = 4.350,
P = < 0.05, partial η2 = 0.592, observed power = 0.921] was
significant. In group A, the numbers of monocytes and
segmented neutrophils decreased (P = 0.002 and P =
0.005) and that of lymphocytes increased (P = 0.020) on
the day following MSC transplantation, while no differ-
ences were detected in group B. In group C, the number
of segmented neutrophils decreased significantly (P =
0.007) (Figure 2).
Serial tests of PT, aPTT, FDP, and D-dimer were con-
ducted to evaluate changes in coagulation status during
the 7 days following allogeneic MSC transplantation. No
significant differences were observed among the serial
test results before and 1, 3, and 7 days after allogeneic
MSC (observed power < 0.80, P > 0.05).
ECG was performed before and after the MSCs treat-
ment (day 1, 3, and 7) in all groups. All wave duration,Figure 2 Evaluation of the difference in cell counts before and after t
before and after MSC transplantation. However, the population of the cells
lymphocyte ratio was increased and segmented neutrophil ratio was decre
B. SegNE: segmented neutrophil; *: P < 0.05; **: P < 0.01. 0 day (before MSCintervals, and height (P width, P height, PR interval, QRS
width, R height, QT interval) were carefully interpreted
and there’s no significant differences before and after the
treatment. No ectopic complexes and arrhythmias were
identified and no changes in ST segment were revealed.
Pulmonary peak flow velocity was measured with the
pulse Doppler pulmonary arterial (PA) flow signal. We
also measured the acceleration time (AT) and ejection
time (ET) of PA flow, and AT:ET ratio was calculated to
alternatively evaluate pulmonary arterial hypertension.
None of the dogs showed pulmonary arterial hyperten-
sion. In all three groups, there were no significant differ-
ences in fractional shortening, ejection fraction, and LA/
AO ratio, and pulmonary peak flow velocity before and 1,
3, and 7 days after allogeneic MSC transplantation (ob-
served power < 0.80, P > 0.05).
Expression level of transcripts for canine TNF-α, IL-4,
IL-6, and IL-10 were different in each group. TNF-α and
IL-6 transcript levels increased 1 day after MSC trans-
plantation in group A, and 3 days after MSC transplant-
ation in groups B and C. IL-4 level was elevated in groups
A and B, whereas it decreased on day 7 in group C. IL-10
level remained elevated in group C, whereas it decreased
3 days post-transplantation in groups A and B. No signifi-
cant difference was observed in the cytokine expression
within groups (observed power < 0.80, P > 0.05) (Figure 3).
MDCT findings
PTE was not detected before and after allogeneic MSCs
transplantation in any of the animals. Only one dog (dog
no. 8) had lung parenchymal changes 7 days after MSCshe MSCs transplantation. The total WBC counts were not changed
was changed, depending on the different groups. In group A and C,
ased (P < 0.05). The ratio of cell population was not changed in group
s transplantation); 1, 3, and 7 days: time after the MSCs transplantation.
Figure 3 Expression of canine TNF-α, IL-4, IL-6, and IL-10 mRNA before and after MSCs transplantation. Expression patterns of pro-
inflammatory cytokines (TNF-α and IL-6) and anti-infalmmatory cytokines (IL-4 and IL-10) were not significant (P > 0.05). RQ: relative quantitation
value. 0 day (before MSCs transplantation); 1, 3, and 7 days: time after the MSCs transplantation.
Table 2 Comparison of MDCT and histopathologic
examination results after MSCs transplantation
MDCT PTE HP PTE MDCT IR HP IR
Number Number Number Number
Left cranial lobe artery (Cr) 0 0 1 1
Left cranial lobe artery (Cd) 0 0 1 2
Left caudal lobe artery 0 0 1 4
Right cranial lobe artery 0 0 1 1
Right middle lobe artery 0 0 1 2
Right caudal lobe artery 0 0 0 3
Accessory lobe artery 0 0 0 1
MDCT vs HP p-value 1.000 0.013*
MDCT multi-detector computed tomography; HP histopathology; PTE pulmonary
thromboembolism; IR inflammatory reaction; Cr cranial part of the left cranial lung
lobe; Cd caudal part of the left caudal lung lobe; number: number of affected
dogs.
*: P < 0.05.
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MSCs for 3 days and showed clinical signs (vomiting)
during transplantation. The dog had infiltrated paren-
chymal changes in all left and two right lung lobes.
Histopathological findings
Upon post-mortem examination, lung parenchymal
changes such as hemorrhage and congestion were iden-
tified in four dogs (one dog from group A and C; two
dogs from group B). However, emboli inside the major
arteries were not evident in any of the dogs. Histopatho-
logic examination of the lung tissue was performed to
detect the presence of lung parenchymal changes as well
as emboli in the lobar and segmental arteries. Mild in-
flammatory reaction such as hemorrhage and edema
were frequently observed in left (n = 4) and right (n = 3)
caudal lung lobes. The cut surface was set, and the inter-
lobular septa were markedly distended with edema fluid.
Only one dog in group C (no. 8 dog) showed severe
hemorrhage, congestion, and inflammation in lung par-
enchyma. These changes were also detected during
MDCT examination.
The results of histopathological examination were
compared with the MDCT analysis results (Table 2).
MDCT and histopathological examination results
showed that PTE was absent in all dogs. MDCT examin-
ation revealed the presence of lung parenchymal changes
in one of the animals. Results of histopathological exam-
inations suggested that lung parenchymal changes were
observed in four animals. Lung parenchymal changes
that were rarely detected in MDCT images were morefrequently revealed during histopathological examination
[t(12) = −2.714, P = 0.013, observed power = 0.700].
Discussion
The efficacy and adverse reaction of the intravenous
MSC infusion remain contentious issues, with pulmon-
ary entrapment, vascular occlusion, and thrombus for-
mation having been described [8,11,19]. MSCs have
been known to function as immunoregulatory cells that
control inflammation [20-22]. However, some reports
have described the cellular and humoral responses
against the allogeneic donor MSCs [23]. Other reports
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icity of MSCs [24].
In the present study, incidence of any adverse reactions,
including the formation of PTE after intravenous injection
of MSCs, were evaluated through various laboratory and
imaging studies. In our study, only one animal showed
clinical signs of adverse reaction during and after allogen-
eic MSCs transplantation. Animals that received 2 × 106
MSCs displayed increased lymphocyte count without ele-
vated number of total WBC (P < 0.01). Laboratory exami-
nations of coagulation profiles, arterial blood gas, and
serum chemistry showed no significant differences. PTE
was not detected and pulmonary parenchymal changes
were detected in one animal by MDCT. This dog showed
acute vomiting twice, 5–10 minutes after the injection of
allogeneic MSCs, and displayed progressive cough, fever,
as well as increased respiratory rate 7 days post-
transplantation. Histopathologic examination revealed
pulmonary hemorrhage, edema, and inflammatory reac-
tion in this dog. The culture for the lung lobes of this dog
was negative; however it was difficult to exclude the possi-
bility of aspiration pneumonia secondary to vomiting.
Three other dogs also displayed pulmonary parenchymal
edema and hemorrhage, the frequently affected regions
being left and right caudal lung lobe. The lung lesions ob-
served could be indicative of possible adverse reactions
after intravenous transplantation of allogeneic MSCs;
however, these results should be interpreted cautiously
owing to the several limitations of this study.
Interestingly, among the three groups, animals that re-
ceived lower dosage of allogeneic MSCs (groups A and C)
showed changes in various WBC populations without an
increase in the total WBC count. Lymphocyte numbers
were elevated in group A, and the number of segmented
neutrophils decreased in groups A and B. Lymphocytosis
in dogs can be caused by antigenic stimulation as well as
immune-mediated and infectious disease [25]. Previous
reports have not described the relationship between MSC
transplantation and WBC population. The exact cause of
the increase in the lymphocyte ratio is not known. We hy-
pothesized that antigenic stimulation due to the allogeneic
MSC transplantation is a potential reason for the observed
changes in the lymphocyte ratio.
We evaluated the expression of the pro-inflammatory
cytokines (TNF-α and IL-6) and anti-inflammatory cyto-
kines (IL-4 and IL-10) before and after allogeneic MSC
transplantation, and no significant changes were ob-
served. However, an acute inflammatory response may
have been missed in this experiment as the circulating
half lives of these cytokines are hours and not days.
Cytokine expression after the transplantation of MSCs
may differ in different environments and species [18].
MSCs inhibit TNF-α secretion, augment the expression of
anti-inflammatory cytokines, and promote IL-6 secretion.Thus, MSCs exhibit the ability to both inhibit and stimu-
late the immune response, a property consistent with their
demonstrated immunomodulatory effects [20,22].
Although PTE was not detected during both MDCT
and histopathological examination, four of nine other
animals displayed pulmonary parenchymal edema and
hemorrhage. On the basis of these results, pulmonary le-
sions after allogeneic MSCs transplantation can be ex-
plained by: (1) obstruction of microcirculation of small
capillaries by infused MSCs; (2) small thrombus forma-
tion, which was not detected during histopathological
examination; and (3) allergic reactions after the allogen-
eic MSC transplantation.
The most important limitation of this study is the lack
of control groups not receiving MSCs transplantation.
The study results suggested the possibility of adverse re-
action during intravenous allogeneic MSC transplant-
ation. Normal dogs which did not receive allogeneic
MSCs were not selected in the experimental control
groups for ethical reasons. Thus, we cannot exclude
other possible effects of some elements during the study
periods, such as anesthetics for MDCT evaluation and
methods of euthanasia and necropsy. Second, to verify
the exact reaction of infused allogeneic MSCs, cell label-
ing and tracking would be needed. Cytotoxic effects of
materials used for cell labeling were studied recently
[26]. Because such effects could potentially influence the
results, cell labeling and tracking were not performed in
this study. In addition, the study results must be inter-
preted cautiously because of the relatively small numbers
of dogs included in each group. Further long-term as-
sessments using large number of dogs and control
groups would be more helpful to demonstrate the safety
and adverse reactions of allogeneic MSC transplantation.
Conclusions
This study attempted to evaluate adverse reaction after
intravenous injection of allogeneic MSCs. One of the
dogs which received MSCs developed clinical signs
(vomiting). Four of the nine dogs developed pulmonary
lesions after the transplantation. On the basis of our re-
sults, we concluded that antigenic stimulation not involv-
ing systemic inflammation, and arising from allogeneic
MSCs transplantation, may serve as a key factor in deter-
mining the post-transplantation lymphocyte ratio. How-
ever, due to the lack of control groups and small number
of study populations, these results should be cautiously
interpreted, and further study would be needed.
Abbreviations
aPTT: Activated partial thromboplastin time; BM: Bone marrow; CBC: Complete
blood cell count; ECG: Electrocardiography; FACS: Fluorescence activated cell
sorter; FDP: Fibrinogen degradation products; IL: Interleukin; MDCT: Multi
detector computed tomography; MSCs: Mesenchymal stem cells;
PT: Prothrombin time; PTE: Pulmonary thromboembolism; RT-PCR: Reverse
transcriptase polymerase chain reaction; TNF-a: Tumor necrosis factor-alpha.
Kang and Park Acta Veterinaria Scandinavica 2014, 56:16 Page 8 of 8
http://www.actavetscand.com/content/56/1/16Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MHK performed the experiments and drafted the manuscript. HMP
participated in the design of the study, coordination and helped writing the
manuscript. Both authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government (MEST) (No. 20100018275).
Received: 14 January 2013 Accepted: 17 March 2014
Published: 21 March 2014
References
1. Bang OY, Lee JS, Lee PH, Lee G: Autologous mesenchymal stem cell
transplantation in stroke patients. Ann Neurol 2005, 57:874–882.
2. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J,
Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT,
Perin EC: Mesenchymal stem cells differentiate into an endothelial
phenotype, enhance vascular density, and improve heart function in a
canine chronic ischemia model. Circulation 2005, 111:150–156.
3. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G,
Wernet P: Repair of infarcted myocardium by autologous intracoronary
mononuclear bone marrow cell transplantation in humans. Circulation
2002, 106:1913–1918.
4. Kursova LV, Konoplyannikov AG, Pasov VV, Ivanova IN, Poluektova MV,
Konoplyannikova OA: Possibilities for the use of autologous mesenchymal
stem cells in the therapy of radiation-induced lung injuries. Bull Exp Biol
Med 2009, 147:542–546.
5. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H,
Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T,
Imaizumi T, Therapeutic Angiogenesis using Cell Transplantation (TACT)
Study Investigators: Therapeutic angiogenesis for patients with limb
ischaemia by autologous transplantation of bone-marrow cells: a pilot
study and a randomised controlled trial. Lancet 2002, 360:427–435.
6. Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D, Lu M, Gautam SC, Chopp
M: Intravenous bone marrow stromal cell therapy reduces apoptosis and
promotes endogenous cell proliferation after stroke in female rat.
J Neurosci Res 2003, 73:778–786.
7. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Choop M: Therapeutic benefit
of intravenous administration of bone marrow stromal cells after
cerebral ischemia in rats. Stroke 2001, 32:1005–1011.
8. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, Wang W,
Yerebakan C, Li W, Gaebel R, Li RK, Vollmar B, Steinhoff G, Ma N: Is the
intravascular administration of mesenchymal stem cells safe?
Mesenchymal stem cells and intravital microscopy. Microvasc Res 2009,
77:370–376.
9. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD: Intra-
coronary arterial injection of mesenchymal stromal cells and
microinfarction in dogs. Lancet 2004, 363:783–784.
10. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L,
Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J: Systemic delivery of bone
marrow-derived mesenchymal stem cells to the infarcted myocardium:
feasibility, cell migration, and body distribution. Circulation 2003,
108:863–868.
11. Kang WJ, Kang HJ, Kim HS, Chung JK, Lee MC, Lee DS: Tissue distribution
of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary
administration in patients with myocardial infarction. J Nucl Med 2006,
47:1295–1301.
12. Jung DI, Kim HJ, Kim JW, Kang BT, Yoo JH, Park C, Lee JH, Park HM: Canine
mesenchymal stem cells derived from bone marrow: isolation,
characterization, multidifferentiation, and neurotrophic factor expression
in vitro. J Vet Clin 2008, 25:458–465.
13. Goncalves AC, Orton EC, Boon JA, Salman MD: Linear, logarithmic, and
polynomial models of m-mode echocardiographic measurements in
dogs. Am J Vet Res 2002, 63:994–999.
14. Boon JA: Manual of Veterinary Echocardiography. 2nd edition. Wiley-Blackwell:
West Sussex, UK; 2011.15. Borqarelli M, Tarducci A, Zanatta R, Haggstrom J: Decreased systolic
function and inadequate hypertrophy in large and small breed dogs
with chronic mitral valve insufficiency. J Vet Intern Med 2007, 21:61–67.
16. Maeda S, Fujiwara S, Omori K, Kawano K, Kurata K, Masuda K, Ohno K,
Tsujimoto H: Lesional expression of thymus and activation-regulated
chemokine in canine atopic dermatitis. Vet Immunol Immunopathol 2002,
88:79–87.
17. Peters IR, Helps CR, Calvert EL, Hall EJ, Day MJ: Cytokine mRNA
quantification in histologically normal canine duodenal mucosa by real-
time RT-PCR. Vet Immunol Immunopathol 2005, 103:101–111.
18. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods
2001, 25:402–408.
19. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI,
Laine GA, Cox CS Jr: Pulmonary passage is a major obstacle for intravenous
stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009,
18:683–692.
20. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood 2005, 105:1815–1822.
21. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A: Treatment of
inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug
Targets 2009, 8:110–123.
22. Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord
P, Domenech J: The in vitro migration capacity of human bone marrow
mesenchymal stem cells: comparison of chemokine and growth factor
chemotactic activities. Stem Cells 2007, 25:1737–1745.
23. Poncelet AJ, Vercruysse J, Saliez A, Gianello P: Although pig allogeneic
mesenchymal stem cells are not immunogenic in vitro, intracardiac
injection elicits an immune response in vivo. Transplantation 2007,
83:783–790.
24. Sundin M, Ringden O, Sundberg B, Nava S, Götherström C, Le Blanc K: No
alloantibodies against mesenchymal stromal cells, but presence of anti-
fetal calf serum antibodies, after transplantation in allogeneic
hematopoietic stem cell recipients. Haematologica 2007, 92:1208–1215.
25. Yagihara H, Uematsu Y, Koike A, Tamura K, Isotani M, Yamaguchi T, Ono K,
Washizu T, Bonkobara M: Immunophenotyping and gene rearrangement
analysis in dogs with lymphoproliferative disorders characterized by
small-cell lymphocytosis. J Vet Diagn Invest 2009, 21:197–202.
26. Lehner B, Sandner B, Marschallinger J, Lehner C, Furtner T, Couillard-Despres
S, Rivera FJ, Brockhoff G, Bauer HC, Weidner N, Aigner L: The dark side of
BrdU in neural stem cell biology: detrimental effects on cell cycle,
differentiation and survival. Cell Tissue Res 2011, 345:313–328.
doi:10.1186/1751-0147-56-16
Cite this article as: Kang and Park: Evaluation of adverse reactions in
dogs following intravenous mesenchymal stem cell transplantation.
Acta Veterinaria Scandinavica 2014 56:16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
